Radionuclide imaging in metabolic and systemic skeletal diseases

Area of Science:

• Nuclear Medicine
• Radiology
• Bone Metabolism

Background:

• Radionuclide imaging with Tc-99m diphosphonates is a common diagnostic tool.
• Its utility in osteoporosis diagnosis is limited due to slow bone loss often remaining undetected.
• However, it excels in identifying focal bone complications.

Purpose of the Study:

• To evaluate the effectiveness of radionuclide imaging in diagnosing various bone diseases.
• To compare its diagnostic value against radiographic findings and biochemical tests.
• To highlight its established role in specific systemic conditions.

Main Methods:

• Review of radionuclide imaging (Tc-99m diphosphonates) applications in bone disease.
• Comparison with radiographic and biochemical diagnostic methods.
• Assessment of imaging's role in osteoporosis, hypercalcemia, and metabolic bone diseases.

Main Results:

• Radionuclide imaging is not effective for detecting or ruling out osteoporosis.
• It is valuable for detecting focal complications like fractures, microfractures, and aseptic necrosis.
• Bone imaging is crucial for investigating hypercalcemia, especially when caused by skeletal metastatic malignancy.
• It aids in assessing skeletal involvement in renal osteodystrophy and shows increased uptake in hyperparathyroidism/osteomalacia.
• Established value in Paget's disease, hypertrophic pulmonary osteoarthropathy, sickle cell disease, fibrous dysplasia, and sympathetic dystrophy.

Conclusions:

• Radionuclide imaging has limited utility in diagnosing osteoporosis but is vital for evaluating focal bone complications and investigating hypercalcemia.
• Its role is significant in specific systemic diseases, complementing other diagnostic modalities.
• Further research into quantitative methods for Tc-99m diphosphonate kinetics is warranted but not widely accepted.